标普和纳斯达克内在价值 联系我们

Item 9 Labs Corp. INLB OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score
24/100
0/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Item 9 Labs Corp. (INLB) .

本页证实的标准:

  • VALUE (0/100, 未通过) — 综合估值评分低于60/100的通过门槛。

SharesGrow 综合评分: 23/100 其中 0/7 项标准通过。

SharesGrow 7-Criteria Score
24/100
SG Score
View full scorecard →
价值
N/A
No coverage
未來
N/A
No coverage
过去
0/100
→ Income
健康
33/100
Debt-to-Equity & liquidity
→ Health
护城河
21/100
→ Income
~
成长
58/100
→ Income
收入
10/100
→ Income

估值概览 — INLB

估值倍数
P/E (TTM)0.0
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率0.00
EV/EBITDA0.0
每股数据
EPS (TTM)$-0.33
每股账面价值$0.00
每股营收$0.23
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
股息收益率0.00%

EPS:实际 vs 预期

P/E Ratio & Earnings Yield

每股收益 (EPS) 历史

Year EPS(稀释) 营收 净利润 净利润率
2013 $-1.94 $341.99K $-3.33M -972.3%
2014 $-6.87 $179.49K $-17.08M -9516.9%
2015 $-1.43 $113.02K $-4.74M -4194.5%
2016 $-0.82 $324.03K $-3.13M -964.6%
2017 $-0.04 $243.93K $-266.57K -109.3%
2018 $-0.23 $1.38M $-642.28K -46.7%
2019 $-0.17 $4.93M $-10.63M -215.5%
2020 $-0.20 $8.12M $-12.3M -151.4%
2021 $-0.21 $21.94M $-16.19M -73.8%
2022 $-0.33 $21.76M $-31.14M -143.1%
联系我们
🎓
SharesGrow 学院
学习如何计算内在价值,发现被低估的股票。
每周在线课程
给我们留言